Monte Rosa Therapeutics, Inc. (GLUE)
Key Executives
| Name | Title | Pay | Exercised | Year Born |
|---|---|---|---|---|
| Dr. Markus Warmuth M.D. | President, CEO & Director | 924.6k | -- | 1971 |
| Dr. Filip Janku M.D., Ph.D. | Chief Medical Officer | 713.2k | -- | 1974 |
| Ms. Jennifer Champoux | Chief Operating Officer | -- | -- | -- |
| Dr. John C. Castle Ph.D. | Chief Data & Information Officer | -- | -- | 1971 |
| Dr. Sharon Townson Ph.D. | Chief Scientific Officer | -- | -- | 1975 |
| Mr. Andrew Funderburk | Senior VP and Head of IR & Strategic Finance | -- | -- | -- |
| Mr. Philip Nickson J.D., Ph.D. | Chief Business & Legal Officer | -- | -- | 1979 |
| Mr. Magnus Walter DPHIL | Senior Vice President of Drug Discovery | -- | -- | -- |
| Mr. Edmund Dunn | Vice President & Corporate Controller | -- | -- | 1966 |
Monte Rosa Therapeutics, Inc.
- Sector:?
- Healthcare
- Industry:? Biotechnology
- Full Time Employees:?
- 129
Description
Monte Rosa Therapeutics, Inc., a clinical-stage biotechnology company, engages in the development of novel small molecule precision medicines that employ the body's natural mechanisms to selectively degrade therapeutically relevant proteins. The company develops MRT-2359, an orally bioavailable molecular glue degrader targeting the translation termination factor protein GSPT1 for the treatment of MYC-driven tumors; MRT-6160 for the treatment of systemic and central nervous system autoimmune diseases; and MRT-8102 for the treatment of IL-1?/NLRP3 driven inflammatory diseases. It also develops CDK2 to treat ovarian, uterine, and breast cancers. The company was incorporated in 2019 and is headquartered in Boston, Massachusetts.
Corporate Governance
Upcoming Events
Upcoming Events Information Not Available